HK Stock Market Move | BIOHEART-B (02185) surged over 31% National Medical Products Administration approved the registration of IBERISRDN system

BIOHEART-B (02185) surged over 31%, reaching 31.58% at the time of the report, with a price of 2.5 Hong Kong dollars and a trading volume of 3.0221 million Hong Kong dollars. On the news front, Bai Xin'an announced that on February 26th, its subsidiary Shanghai Antong Medical Technology Co., Ltd. developed the Iberis multipolar renal artery radiofrequency ablation system (including disposable multipolar renal artery radiofrequency ablation catheters and renal artery radiofrequency ablation devices) (Iberis RDN system), has been approved by the China National Medical Products Administration for use in assisting the treatment of refractory hypertension and hypertension patients who are intolerant to medication. Daibang Securities previously stated in its research report that Iberis is the only global renal artery ablation product that can provide two intervention methods, and it has a relatively small catheter sheath size, which is expected to quickly capture the market with its first-mover advantage and strong product performance.